Department of Medicinal Chemistry, University of Utah , Salt Lake City, Utah 84112 United States.
Acc Chem Res. 2017 Oct 17;50(10):2569-2576. doi: 10.1021/acs.accounts.7b00330. Epub 2017 Sep 11.
Natural products are significant therapeutic agents and valuable drug leads. This is likely owing to their three-dimensional structural complexity, which enables them to form complex interactions with biological targets. Enzymes from natural product biosynthetic pathways show great potential to generate natural product-like compounds and libraries. Many challenges still remain in biosynthesis, such as how to rationally synthesize small molecules with novel structures and how to generate maximum chemical diversity. In this Account, we describe recent advances from our laboratory in the synthesis of natural product-like libraries using natural biosynthetic machinery. Our work has focused on the pat and tru biosynthetic pathways to patellamides, trunkamide, and related compounds from cyanobacterial symbionts in marine tunicates. These belong to the cyanobactin class of natural products, which are part of the larger group of ribosomally synthesized and post-translationally modified peptides (RiPPs). These results have enabled the synthesis of rationally designed small molecules and libraries covering more than 1 million estimated derivatives. Because the RiPPs are translated on the ribosome and then enzymatically modified, they are highly compatible with recombinant technologies. This is important because it means that the resulting natural products, their derivatives, and wholly new compounds can be synthesized using the tools of genetic engineering. The RiPPs also represent possibly the most widespread group of bioactive natural products, although this is in part because of the broad definition of what constitutes a RiPP. In addition, the underlying ideas may form the basis for broad-substrate biosynthetic pathways beyond the RiPPs. For example, some of the ideas about kinetic ordering of broad substrate pathways may apply to polyketide or nonribosomal peptide biosynthesis as well. While making these products, we have sought to understand what makes biosynthetic pathways plastic and whether there are any rules that might generally apply to plastic biosynthetic pathways. We present three principles of diversity-generating biosynthesis: (1) substrate evolution, in which the substrates change while enzymes remain constant; (2) pairing of recognition sequences on substrates with biosynthetic enzymes; (3) an inverse metabolic flux in comparison to canonical pathways. If these principles are general, they may enable the design of unimagined derivatives using biosynthetic engineering. For example, it is possible to discover substrate evolution directly by examining sequencing data. By shuffling appropriate recognition sequences and biosynthetic enzymes, it has already been possible to make new hybrid products of multiple pathways. While cases so far have been limited, if this is more general, designed synthesis will become routine. Finally, biosynthesis of natural products is regulated in elaborate ways that are just beginning to be understood. If the inverse metabolic flux model is widespread, it potentially informs on what the timing and relative production level of each enzyme in a designer pathway should be in order to optimize the synthesis of new compounds in vivo.
天然产物是重要的治疗药物和有价值的药物先导化合物。这可能是由于其三维结构的复杂性,使它们能够与生物靶标形成复杂的相互作用。天然产物生物合成途径中的酶具有产生天然产物类似化合物和文库的巨大潜力。然而,生物合成仍然存在许多挑战,例如如何合理地合成具有新颖结构的小分子,以及如何产生最大的化学多样性。在本报告中,我们描述了我们实验室使用天然生物合成机制合成天然产物类似文库的最新进展。我们的工作主要集中在 pat 和 tru 生物合成途径上,以从海洋被囊动物中的蓝细菌共生体中获得 patellamides、trunkamide 和相关化合物。这些化合物属于 cyanobactin 类天然产物,是核糖体合成和翻译后修饰肽 (RiPPs) 这一大类的一部分。这些结果使我们能够合成合理设计的小分子和文库,涵盖了超过 100 万个估计的衍生物。由于 RiPPs 在核糖体上翻译,然后被酶修饰,因此它们与重组技术高度兼容。这很重要,因为这意味着可以使用遗传工程的工具来合成天然产物、它们的衍生物和全新的化合物。RiPPs 还代表了可能是最广泛的一类生物活性天然产物,尽管这在一定程度上是因为 RiPP 所包含的定义范围很广。此外,这些想法可能为超越 RiPP 的广泛底物生物合成途径奠定基础。例如,一些关于广泛底物途径的动力学排序的想法可能也适用于聚酮体或非核糖体肽的生物合成。在生产这些产品的过程中,我们试图了解是什么使生物合成途径具有可塑性,以及是否有任何一般适用于可塑性生物合成途径的规则。我们提出了三种产生多样性的生物合成原则:(1)底物进化,其中底物发生变化而酶保持不变;(2)底物与生物合成酶上的识别序列配对;(3)与典型途径相比,代谢通量的反转。如果这些原则是普遍的,它们可能使我们能够使用生物合成工程设计出以前无法想象的衍生物。例如,可以通过检查测序数据直接发现底物进化。通过混合适当的识别序列和生物合成酶,已经有可能制造出多种途径的新杂交产物。虽然到目前为止这种情况还很有限,但如果这更普遍,那么设计合成将成为常规。最后,天然产物的生物合成受到复杂的调控,而这些调控机制才刚刚开始被理解。如果代谢通量反转模型是普遍存在的,那么它可能会告诉我们,为了优化新化合物在体内的合成,设计途径中每个酶的时间和相对产生水平应该是什么。